Biogen Inc. (NASDAQ:BIIB) is one of the best stem cell therapy stocks to buy. On April 22, Biogen Inc. (NASDAQ:BIIB) was upgraded to Buy from Neutral by UBS, with the firm adjusting the price target ...
The Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation to Biogen for a ...
Biogen heads into Q1 earnings with new drugs like Skyclarys and Zurzuvae driving growth as legacy MS products face rising competitive pressure.
'Mad Money' host Jim Cramer weighs in on stocks including: AES, InterDigital, Infleqtion, Netskope, and Biogen.
April 20 () - Biogen said on Monday it had agreed to pay up to $850 million to acquire exclusive rights in Greater China to ...
The investment bank upgraded the pharmaceutical name to buy from neutral. It also hiked its price target on shares to $225 ...
Biogen (NASDAQ:BIIB) stock just earned a strong endorsement from Wells Fargo on Monday, as analyst Mohit Bansal upgraded the ...
Fintel on MSN
UBS upgrades Biogen (BIIB)
Fintel reports that on April 22, 2026, UBS upgraded their outlook for Biogen (NasdaqGS:BIIB) from Neutral to Buy. Analyst ...
US biotech major Biogen and TJ Biopharma have entered into a definitive agreement under which Biogen has agreed to acquire TJ ...
India’s Sun Pharmaceutical Industries agrees to buy the women’s health company for $14 a share in an all-cash deal.
In a report released today, Emily Field from Barclays maintained a Hold rating on Biogen, with a price target of $185.00. According to TipRanks, Field is a 3-star analyst with an average return of 1.4 ...
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Biogen , Nektar Therapeutics and GE Healthcare Technologies Inc . Claim 30% Off TipRanks. Unlock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results